Skip to main content

Table 5 The efficacy of aliskiren in heart failure

From: Clinical efficacy, safety and tolerability of Aliskiren Monotherapy (AM): an umbrella review of systematic reviews

OutcomeNo. of SRsNo. of original studiesNo. of cases/controlsFollow-up range (weeks)Type of metricEstimate (95%CI)P-value95%PII2(P*)Egger’s P value
aliskiren vs placebo
 NT-proBNP levels13975/95612–48SMD−0.12 [−0.21,-0.03]0.01[−0.70,0.46]0% (0.57)0.814
 BNP levels12151/1436–12SMD−0.08 [−0.31,0.15]0.49NA0%(0.76)NA
 Plasma renin activity13176/15712–48SMD−0.66 [−0.89,-0.44]< 0.0001[−2.11,0.77]0%(0.85)0.648
 Plasma renin concentration12167/1496–26SMD0.52 [0.30,0.75]< 0.0001NA0%(0.72)NA
 Aldosterone level12151/1436–12SMD−0.09 [−0.32,0.14]0.44NA0%(0.55)NA
 Mortality231255/1250≥12RR0.76 [0.32–1.80]0.53[0.00,3273.53]24%(0.27)0.498
 Myocardial infarction11305/308104RR0.13[0.02–1.00]0.05NANANA
 Stroke11305/308104RR0.25 [0.03–2.25]0.22NANANA
aliskiren vs enalapril
 Combined cardiovascular mortality and hospitalisation112340/233636RR0.98 [0.90–1.06]0.57NANANA